-
Our patented 1C-SApNP Platform Technology
offers a robust pipeline of promising vaccine candidates to address global health challenges
such as the COVID pandemic, as well as HIV, RSV, HCV, Ebola, Malaria, and Tuberculosis -
Promising COVID-19 vaccine candidates for evaluation
Science Advances publishes research article on Uvax-2129,
Uvax Bio’s patented solution to COVID-19Clinical trials to start mid-late 2021
-
New Patent Allowed
Uvax Bio’s pioneering HCV vaccine design has been allowed by the US Patent Office
Latest News
Reshaping The Vaccine Manufacturing Paradigm
By Matthew Pillar, Editor, BioProcess Online Uvax Bio’s unconventional approach brings a heretofore ignored physical component to vaccine design. Co-founders Dr. Ji Li and Jiang Zhu share why they think their platform is poised to revolutionize vaccine development, manufacturing, and distribution. Launching a biotech wasn’t… [Read more]
Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates
Three coronaviruses (CoVs) have caused widespread outbreaks in humans, including severe acute respiratory syndrome CoV-1 (SARS-CoV-1), Middle East respiratory syndrome CoV (MERS-CoV), and SARS-CoV-2, which is the causative agent of CoV disease 2019 (COVID-19) (1–3) and has resulted in more than 2.4 million deaths worldwide… [Read more]
About Uvax Bio
Founded in early 2018, Uvax Bio, a spin-off vaccine company from Scripps Research, La Jolla, CA, employs patented single-component self-assembling protein nanoparticle (1c-SApNP) platform technology developed by Professor Jiang Zhu of Scripps Research to develop and commercialize B-cell focused, rapid antibody-eliciting, preventive vaccines for the most challenging diseases around the world.
Our 1c-SApNP technology streamlines vaccine development and has delivered promising vaccine candidates to address global health challenges such as HIV, RSV/hMPV, PIV1-5, Ebola/Marburg, Lassa, coronaviruses including SARS-CoV, MERS-CoV and SARS-CoV-2, HCV, ZIKV/DENV, and non-viral diseases such as Malaria and Tuberculosis.